Predicting Prostate Cancer Biochemical Recurrence Using a Panel of Serum Proteomic Biomarkers

Journal of Urology

Volumn 181, Issue 3, 2009, Pages 1407-1414

  Rosenzweig, C Nicole ^a   Zhang, Zhen ^a   Sun, Xiaer ^a   Sokoll, Lori J ^a   Osborne, Katherine ^a   Partin, Alan W ^a   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

complement C4a; neoplasm recurrence; prostate; prostatic neoplasms; protein C inhibitor

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4A; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ROC CURVE; SERUM;

BIOLOGICAL MARKERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 59349092682     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.10.142     Document Type: Article

References (14)

1. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
2. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
3. Cooperberg M.R., Pasta D.J., Elkin E.P., Litwin M.S., Latini D.M., Du Chane J., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (2005) 1938
4. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445
5. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116 (2006) 271
6. Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., Yi J., Schuchard M.D., et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5 (2005) 3262
7. Grayhack J.T., Wendel E.F., Oliver L., and Lee C. Analysis of specific proteins in prostatic fluid for detecting prostatic malignancy. J Urol 121 (1979) 295
8. Moroni M., Porta C., De Amici M., Quaglini S., Cattabiani M.A., and Buzio C. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 85 (2000) 298
9. Lin Y., Goedegebuure P.S., Tan M.C., Gross J., Malone J.P., Feng S., et al. Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res 5 (2006) 2169
10. Deperthes D., Chapdelaine P., Tremblay R.R., Brunet C., Berton J., Hebert J., et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1245 (1995) 311
11. Bourgeois L., Brillard-Bourdet M., Deperthes D., Juliano M.A., Juliano L., Tremblay R.R., et al. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. J Biol Chem 272 (1997) 29590
12. Christensson A., and Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 220 (1994) 45
13. Laurell M., Christensson A., Abrahamsson P.A., Stenflo J., and Lilja H. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 89 (1992) 1094
14. Cao Y., Becker C., Lundwall A., Christensson A., Gadaleanu V., Lilja H., et al. Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate 57 (2003) 196